MajorAntiplatelet agents (low dose) / NSAIDs (analgesic dose)×Direct oral anticoagulants (factor Xa inhibitors)
Updated · Methodology
Mechanism
Edoxaban directly and reversibly inhibits coagulation factor Xa (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). Acetylsalicylic acid irreversibly inhibits platelet aggregation by blocking platelet cyclooxygenase (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). Acetylsalicylic acid 100 mg or 325 mg given with edoxaban prolonged bleeding time more than either drug alone (EMA). High-dose acetylsalicylic acid (325 mg) raised steady-state edoxaban Cmax by 35% and AUC by 32%. A low dose of 100 mg or less did not change edoxaban exposure (EMA). In edoxaban clinical studies, major bleeding was roughly twice as frequent with concomitant low-dose acetylsalicylic acid, other antiplatelets and thienopyridines. Even so, major bleeding was about as frequent with edoxaban as with warfarin (EMA).
Symptoms
The risk of bleeding rises. Bleeding can occur at any site and may be severe or even fatal (edoxaban summary of product characteristics, SmPC, European Medicines Agency, EMA). The most frequently reported adverse reactions with edoxaban are nosebleeds, blood in the urine and anaemia. Common adverse reactions also include gastrointestinal bleeding, bleeding in the mouth and throat, bleeding into the skin and soft tissues, and vaginal bleeding (EMA). Bleeding complications may present as weakness, pallor, dizziness, headache, unexplained swelling, shortness of breath or shock with no apparent cause (EMA). With acetylsalicylic acid, black stools, vomiting blood, a drop in blood pressure, cold sweat, abdominal pain and dizziness may signal bleeding, especially from the upper gastrointestinal tract (acetylsalicylic acid SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS).
Management
The combination is not contraindicated, but whenever possible, avoid combining acetylsalicylic acid with anticoagulants, edoxaban included. If the combination is judged necessary, use it with caution and warn the patient about the signs of bleeding (acetylsalicylic acid summary of product characteristics, SmPC, Spanish Agency of Medicines and Medical Devices, AEMPS). If the combination cannot be avoided, the same SmPC calls for careful monitoring of the INR, the international normalised ratio (AEMPS). The edoxaban SmPC, however, says that standard laboratory tests cannot reliably monitor the anticoagulant effect of edoxaban (edoxaban SmPC, European Medicines Agency, EMA). Low-dose acetylsalicylic acid, up to 100 mg a day, can be taken with edoxaban. Give doses above 100 mg only under medical supervision. The edoxaban SmPC does not recommend long-term high-dose acetylsalicylic acid (325 mg) with edoxaban (EMA). In older patients, combine edoxaban and acetylsalicylic acid with caution because of a potentially higher risk of bleeding (EMA). If haemoglobin or blood pressure falls without explanation, look for a bleeding site, and stop edoxaban if severe bleeding occurs (EMA). According to the US edoxaban label, monitor patients who need long-term low-dose acetylsalicylic acid carefully for bleeding (edoxaban prescribing information, US Food and Drug Administration, FDA).
Your whole list in one report
Up to 15 drugs: every pair in one table and a PDF report. Your first report is free: we only ask for your email
Add more drugsMedicine list: everything you take in one place →
Sources
- AEMPS: Ficha técnica: Ácido acetilsalicílico, Adiro 100 mg (nº registro 62825) (2026)– AEMPS, CIMA, nº registro 62825 (Adiro 100 mg comprimidos gastrorresistentes EFG), revisión 07/2026, secciones 4.3, 4.4 y 4.5
- FDA: SAVAYSA (edoxaban) tablets, prescribing information (2023)– FDA, SAVAYSA (edoxaban tosylate) prescribing information, Daiichi Sankyo, NDA 206316, revised 10/2023 (DailyMed)
- EMA: Ficha técnica: Edoxabán, Lixiana 60 mg (EU/1/15/993), secciones 4.4 y 4.5 (2025)– EMA, ficha técnica de Lixiana 60 mg comprimidos recubiertos con película (Daiichi Sankyo Europe), EU/1/15/993, texto en CIMA nº registro 115993018, información del producto de la EMA actualizada 27/08/2025, secciones 4.2, 4.3, 4.4, 4.5, 4.8, 4.9 y 5.2